J&J, Roche, Celgene and others power new cancer-drug wave

In the world of cancer drugs, calling a new entry "the next Avastin" or "the next Gleevec" is like picking out the next Brad Pitt or the next Beyoncé. Those two treatments were among a crop of future blockbusters launched as the new millennium kicked into gear, and they're top sellers today. But that's just what the IMS Institute for Healthcare Informatics is doing in its latest report on the pharma business. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.